Peroxisome proliferator-activated receptor y agonists

Buckingham, R. E., Al-Barazanji, K. A., Toseland, C. 1). N. el al. (1998). Peroxisome Proliferator-Activated Receptor-y Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rrts. Diabetes 47, 1326-1334. 

Burris TP, Pelton PD, Zhou L, et al. A novel method for analysis of nuclear receptor function at natural promoters peroxisome proliferator-activated receptor y agonist actions on a P2 gene expression detected using branched DNA messenger RNA quantitation. Mol Endocrinol 1999 13 410—417. 

Grey, A., Bolland, M., Gamble, G. et al. (2007) The peroxisome proliferator-activated receptor y agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women a randomized,... 

Peroxisome Proliferator-Activated Receptor y-Agonists and Stroke... 

Natarajan, C. and J.J. Bright. Peroxisome Proliferator-Activated Receptor-y Agonists Inhibit Experimental Allergic Encephalomyelitis by Blocking IL-12 Production, IL-12 Signaling andThl Differentiation. enesJnujujji 3 59-70 (2002). 

Tang SC, Leung JC, Chan LY, Tsang AW, and Lai KN. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-y agonist./Amer Soc Afep/jm/, 17 1633-1643(2006). 

Thiazolidinediones (PPARy-agonists) Thiazolidine-diones ( pioglitazone, rosiglitazone) lower blood glucose levels in animal models of insulin resistance and also in insulin resistant patients. They are agonists of the peroxisome proliferator-activated receptor y (PPARy). Because they enhance the effect of insulin and reduce serum insulin levels in insulin resistant patients, thiazolidinediones are usually referred to as insulin sensitizers . 

Rosiglitazone 9, an agonist of peroxisome proliferator activated receptor-y (PPARy), is a recently introduced antihyperglycemic thiazolidinedione effective in the treatment of noninsulin dependant diabetes mellitus (type II diabetes). A seven-step synthesis was developed (Scheme 3), which utilised supported reagents in combination with in-line SPE purifications. The introduction of the pyridine moiety provided a convenient molecular handle by which to purify the molecule throughout the synthesis. Notably, the overall yield (46%) for this synthesis was higher than the yield reported in the initial shorter solution-phase synthesis (31%). ... 

PCSK9, proprotein convertase subtUisin/kexin type 9 PPAR-y, peroxisome-proliferator-activated receptor-y receptor agonists PPG, post-prandial... 

Burgermeister, E., Schnoebelen, A., Flament, A. et al. (2006) A novel partial agonist of peroxisome proliferator-activated receptor-y (PPARy) recruits PPARy-coactivator-la, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Molecular Endocrinology, 20, 809-830. 

Qin, C., Morrow, D., Stewart, J., Spencer, K., Porter, W., Smith, R., Ill, Phillips, T., Abdelrahim, M., Samudio, I. and Safe, S. (2004) A new class of peroxisome proliferator-activated receptor y (PPARy) agonists that inhibit growth of breast cancer cells l,l-bis(3 -indolyl)-l-(p-substituted phenyljmethanes. Molecular Cancer Therapeutics, 3, 247-259. 

Sun H, Huang Y, Yu X, Li Y, Yang J, Li R, Deng Y, Zhao G (2008) Peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, suppresses CD40 expression and attenuates inflammatory responses after hthium pilocarpine-induced status epilepticus in rats. Int J Neurosci 26 505-515... 

Hong, J.T., Lee, M.K., Park, K.S., Jung, K.M., Lee, R.D., Jung, H.K., Park, K.L, Yang, K.J. Chung, Y.S. (2002) Inhibitory effect of peroxisome proliferator-activated receptor gamma agonist on ochratoxin A-induced cytotoxicity and activation of transcription factors in cultured rat embryonic midbrain cells. J. Toxicol. Environ. Health A 65, 407—418. 

---